Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

1841. Comparison of alprazolam, imipramine, and placebo in the treatment of depression.

Comparison of alprazolam, imipramine, and placebo in the treatment of depression. 6133970 1983 07 08 1983 07 08 2016 10 17 0098-7484 249 22 1983 Jun 10 JAMA JAMA Comparison of alprazolam, imipramine, and placebo in the treatment of depression. 3057-64 Alprazolam is the first of the triazolobenzodiazepines to be studied in a large population of depressed patients. In a six-week, double-blind multicenter comparison of alprazolam, imipramine hydrochloride, and placebo in the treatment of 723 (...) patients with depression, the two active drugs were statistically more effective than placebo. Alprazolam was at least as effective as imipramine in relieving depressive symptoms, significantly more effective in relieving somatic symptoms, and showed an earlier onset of activity in some measurements. Anticholinergic side effects were reported most often by patients receiving imipramine, while drowsiness was the only side effect reported most often in the alprazolam group. The Feighner Diagnostic

JAMA1983

1842. Double-blind controlled trail of electroconvulsive therapy (E.C.T.) and simulated E.C.T. in depressive illness.

Double-blind controlled trail of electroconvulsive therapy (E.C.T.) and simulated E.C.T. in depressive illness. 76748 1978 06 12 1978 06 12 2015 06 16 0140-6736 1 8067 1978 Apr 08 Lancet (London, England) Lancet Double-blind controlled trail of electroconvulsive therapy (E.C.T.) and simulated E.C.T. in depressive illness. 738-40 40 patients prescribed electroconvulsive therapy (E.C.T.) for treatment of a depressive illness were randomly allocated to two groups. One group had the first two E.C.T (...) . treatments replaced by simulated E.C.T. on a double-blind basis. The results show that E.C.T. is significantly superior to simulated E.C.T. in the treatment of depressive illness. Freeman C P CP Basson J V JV Crighton A A eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 AIM IM Adult Aged Clinical Trials as Topic Depression therapy Double-Blind Method Electroconvulsive Therapy Evaluation Studies as Topic Female Humans Male Manifest Anxiety

Lancet1978